FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385576170> ?p ?o ?g. }

• W4385576170 endingPage "916" @default.
• W4385576170 startingPage "916" @default.
• W4385576170 abstract "It has been consistently demonstrated that circulating lipids and particularly low-density lipoprotein cholesterol (LDL-C) play a significant role in the development of coronary artery disease (CAD). Several trials have been focused on the reduction of LDL-C values in order to interfere with atherothrombotic progression. Importantly, for patients who experience acute coronary syndrome (ACS), there is a 20% likelihood of cardiovascular (CV) event recurrence within the two years following the index event. Moreover, the mortality within five years remains considerable, ranging between 19 and 22%. According to the latest guidelines, one of the main goals to achieve in ACS is an early improvement of the lipid profile. The evidence-based lipid pharmacological strategy after ACS has recently been enhanced. Although novel lipid-lowering drugs have different targets, the result is always the overexpression of LDL receptors (LDL-R), increased uptake of LDL-C, and lower LDL-C plasmatic levels. Statins, ezetimibe, and PCSK9 inhibitors have been shown to be safe and effective in the post-ACS setting, providing a consistent decrease in ischemic event recurrence. However, these drugs remain largely underprescribed, and the consistent discrepancy between real-world data and guideline recommendations in terms of achieved LDL-C levels represents a leading issue in secondary prevention. Although the cost-effectiveness of these new therapeutic advancements has been clearly demonstrated, many concerns about the cost of some newer agents continue to limit their use, affecting the outcome of patients who experienced ACS. In spite of the fact that according to the current recommendations, a stepwise lipid-lowering approach should be adopted, several more recent data suggest a strike early and strike strong strategy, based on the immediate use of statins and, eventually, a dual lipid-lowering therapy, reducing as much as possible the changes in lipid-lowering drugs after ACS. This review aims to discuss the possible lipid-lowering strategies in post-ACS and to identify those patients who might benefit most from more powerful treatments and up-to-date management." @default.
• W4385576170 created "2023-08-05" @default.
• W4385576170 creator A5000206751 @default.
• W4385576170 creator A5002909459 @default.
• W4385576170 creator A5006122223 @default.
• W4385576170 creator A5015330640 @default.
• W4385576170 creator A5036360168 @default.
• W4385576170 creator A5043330302 @default.
• W4385576170 creator A5044850921 @default.
• W4385576170 creator A5049885431 @default.
• W4385576170 creator A5053905470 @default.
• W4385576170 creator A5059166446 @default.
• W4385576170 creator A5059807600 @default.
• W4385576170 creator A5068319384 @default.
• W4385576170 creator A5070583620 @default.
• W4385576170 creator A5081676409 @default.
• W4385576170 creator A5084847484 @default.
• W4385576170 creator A5085247495 @default.
• W4385576170 date "2023-08-04" @default.
• W4385576170 modified "2023-10-16" @default.
• W4385576170 title "Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update" @default.
• W4385576170 cites W127809968 @default.
• W4385576170 cites W1520609538 @default.
• W4385576170 cites W1551289483 @default.
• W4385576170 cites W1888435097 @default.
• W4385576170 cites W1994847711 @default.
• W4385576170 cites W1996038402 @default.
• W4385576170 cites W1998569580 @default.
• W4385576170 cites W2005962533 @default.
• W4385576170 cites W2016002330 @default.
• W4385576170 cites W2018711158 @default.
• W4385576170 cites W2026553345 @default.
• W4385576170 cites W2027415701 @default.
• W4385576170 cites W2029270606 @default.
• W4385576170 cites W2040462758 @default.
• W4385576170 cites W2052094004 @default.
• W4385576170 cites W2053082244 @default.
• W4385576170 cites W2054943565 @default.
• W4385576170 cites W2063604501 @default.
• W4385576170 cites W2070396041 @default.
• W4385576170 cites W2071155446 @default.
• W4385576170 cites W2074457485 @default.
• W4385576170 cites W2087619861 @default.
• W4385576170 cites W2094737030 @default.
• W4385576170 cites W2098332177 @default.
• W4385576170 cites W2100800328 @default.
• W4385576170 cites W2103108681 @default.
• W4385576170 cites W2104269881 @default.
• W4385576170 cites W2108186811 @default.
• W4385576170 cites W2121037015 @default.
• W4385576170 cites W2127791131 @default.
• W4385576170 cites W2130192610 @default.
• W4385576170 cites W2137983259 @default.
• W4385576170 cites W2138544596 @default.
• W4385576170 cites W2139168645 @default.
• W4385576170 cites W2148173161 @default.
• W4385576170 cites W2151495858 @default.
• W4385576170 cites W2153788691 @default.
• W4385576170 cites W2156125238 @default.
• W4385576170 cites W2159449551 @default.
• W4385576170 cites W2160152341 @default.
• W4385576170 cites W2164089346 @default.
• W4385576170 cites W2164324917 @default.
• W4385576170 cites W2168628873 @default.
• W4385576170 cites W2169252817 @default.
• W4385576170 cites W2226868126 @default.
• W4385576170 cites W2247997571 @default.
• W4385576170 cites W2253702257 @default.
• W4385576170 cites W2288779759 @default.
• W4385576170 cites W2331959986 @default.
• W4385576170 cites W2342919462 @default.
• W4385576170 cites W2402427708 @default.
• W4385576170 cites W2465758073 @default.
• W4385576170 cites W2520709760 @default.
• W4385576170 cites W2554832534 @default.
• W4385576170 cites W2566015011 @default.
• W4385576170 cites W2570432860 @default.
• W4385576170 cites W2589580491 @default.
• W4385576170 cites W2595169180 @default.
• W4385576170 cites W2595226750 @default.
• W4385576170 cites W2609543937 @default.
• W4385576170 cites W2614578122 @default.
• W4385576170 cites W2743198652 @default.
• W4385576170 cites W2746706677 @default.
• W4385576170 cites W2747380632 @default.
• W4385576170 cites W2748800769 @default.
• W4385576170 cites W2751210700 @default.
• W4385576170 cites W2769252393 @default.
• W4385576170 cites W2771232411 @default.
• W4385576170 cites W2780743843 @default.
• W4385576170 cites W2789663994 @default.
• W4385576170 cites W2799954281 @default.
• W4385576170 cites W2808641584 @default.
• W4385576170 cites W2889378692 @default.
• W4385576170 cites W2898519070 @default.
• W4385576170 cites W2899066146 @default.
• W4385576170 cites W2899997727 @default.
• W4385576170 cites W2900034165 @default.

• next